Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Fiche publication
Date publication
août 2015
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS
Lien Pubmed
Résumé
Although epidermal growth factor receptor (EGFR) -mutated adenocarcinomas initially have high response rates to EGFR tyrosine kinase inhibitors (TKIs), most patients eventually develop resistance. Patient-derived xenografts (PDXs) are considered preferred preclinical models to study the biology of patient tumors. EGFR-mutant PDX models may be valuable tools to study the biology of these tumors and to elucidate mechanisms of resistance to EGFR-targeted therapies.
Mots clés
Adenocarcinoma, metabolism, Adenocarcinoma of Lung, Afatinib, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Agents, pharmacology, Biomarkers, Tumor, analysis, Carcinoma, Non-Small-Cell Lung, drug therapy, Cetuximab, Crizotinib, Drug Resistance, Neoplasm, ErbB Receptors, drug effects, Erlotinib Hydrochloride, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Heterografts, Humans, Lung Neoplasms, drug therapy, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Mutation, Predictive Value of Tests, Prognosis, Protein Kinase Inhibitors, pharmacology, Protein-Tyrosine Kinases, antagonists & inhibitors, Pyrazoles, administration & dosage, Pyridines, administration & dosage, Quinazolines, administration & dosage, Quinazolinones, administration & dosage, Signal Transduction, Up-Regulation
Référence
J. Clin. Oncol.. 2015 Aug 1;33(22):2472-80